IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results
IRADIMED CORPORATION (NASDAQ: IRMD) reported third-quarter 2021 revenue of $10.9 million, a significant increase from $7.7 million in Q3 2020. The company achieved a GAAP diluted EPS of $0.20 and a non-GAAP diluted EPS of $0.23. For the nine months ended September 30, 2021, revenue reached $29.9 million, up from $23.2 million in the same period of 2020. The company has increased its full-year guidance, anticipating revenue of $41.4 million to $41.6 million and GAAP diluted EPS of $0.60 to $0.61.
- Revenue for Q3 2021 rose to $10.9 million, a 41.7% increase YoY.
- GAAP diluted EPS increased to $0.20, up from $0.09 in Q3 2020.
- Non-GAAP diluted EPS improved to $0.23, compared to $0.11 for Q3 2020.
- For nine months ended September 30, 2021, revenue was $29.9 million, a 28.8% increase YoY.
- The company raised full-year revenue guidance to $41.4 million - $41.6 million, previously $40.0 million - $40.4 million.
- None.
- Reports third quarter 2021 revenue of
$10.9 million , GAAP diluted EPS of$0.20 and non-GAAP diluted EPS of$0.23 - Increases full-year 2021 financial guidance
WINTER SPRINGS, Fla., Oct. 29, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three and nine months ended September 30, 2021.
“I am pleased with these financial results and continue to be proud of our performance and resiliency in an everchanging environment marked by the continued uncertainties of COVID. With these financial results, we are on pace to post approximately 8 percent revenue growth over the pre-COVID 2019 year as well as achieve the highest full-year revenue in Iradimed’s history,” said Roger Susi, President and Chief Executive Officer of the Company.
Three Months Ended September 30, 2021
For the third quarter ended September 30, 2021, the Company reported revenue of
Non-GAAP net income was
Nine Months Ended September 30, 2021
For the nine months ended September 30, 2021, the Company reported revenue of
Non-GAAP net income was
Revenue Information:
| Three Months Ended | Nine Months Ended | ||||||||||
| September 30, | September 30, | ||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||
| (unaudited) | (unaudited) | ||||||||||
| Devices: | |||||||||||
| MRI compatible IV infusion pump system | $ | 3,369,068 | $ | 2,153,699 | $ | 9,329,182 | $ | 6,693,692 | |||
| MRI Compatible Patient Vital Signs Monitoring Systems | 3,779,442 | 2,282,943 | 9,760,991 | 6,829,932 | |||||||
| Total Devices revenue | 7,148,510 | 4,436,642 | 19,090,173 | 13,523,624 | |||||||
| Disposables, services and other | 3,285,656 | 2,802,039 | 9,412,091 | 8,269,487 | |||||||
| Amortization of extended warranty agreements | 473,136 | 460,415 | 1,439,457 | 1,378,218 | |||||||
| Total revenue | $ | 10,907,302 | $ | 7,699,096 | $ | 29,941,721 | $ | 23,171,329 | |||
For the third quarter 2021, domestic sales were 79.5 percent of total revenue, compared to 84.0 percent for the third quarter 2020. Gross profit margin was 77.1 percent for the third quarter 2021, compared to 74.6 percent for the third quarter 2020.
For the nine months ended September 30, 2021, domestic sales were 80.1 percent of total revenue, compared to 75.2 percent for the same period in 2020. Gross profit margin was 76.1 percent for the nine months ended September 30, 2021, compared to 73.9 percent for the same period in 2020.
Cash Flow:
For the nine months ended September 30, 2021, cash from operations was
For the third quarter ended September 30, 2021, free cash flow was
Financial Guidance
For the fourth quarter 2021, the Company expects to report revenue of
The Company increased its full-year financial guidance, and now expects to report revenue of
The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax, which the Company expects to be approximately
Use of non-GAAP Financial Measures
The Company believes the use of non-GAAP net income, free cash flow and infrequent income tax items are helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with U.S. GAAP.
We calculate non-GAAP net income as net income excluding (1) stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period; (2) operating expenses, net of tax, that we believe are not indicative of the Company’s on-going core operating performance, and; (3) infrequent tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes. We calculate free cash flow as net cash provided by operating activities, less net cash used in investing activities for purchases of property and equipment.
We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our shareholders through various means.
All of our non-GAAP financial measures are important tools for financial and operational decision making and for evaluating our on-going core operating results.
A reconciliation of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of cash flows. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with U.S. GAAP and are not indicative of net income or cash provided by operating activities.
Conference Call
IRADIMED has scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time today, October 29, 2021. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering the reservation code 1675895.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging (“MRI”) compatible medical devices. We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.
For more information please visit www.iradimed.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Act of 1995, particularly statements regarding our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. These statements relate to future events or our future financial performance or condition and involve unknown risks, uncertainties and other factors that could cause our actual results, level of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. The risks and uncertainties referred to above include, but are not limited to, risks associated with the Company’s ability to receive an EC Certificate or CE Mark for our existing products and product candidates, receive FDA 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management’s attention associated with the design, manufacture or sale of new products; the Company’s ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; potential disruptions in our limited supply chain for our products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations.
Further information on these and other factors that could affect the Company’s financial results is included in filings we make with the Securities and Exchange Commission from time to time. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.
IRADIMED CORPORATION
CONDENSED BALANCE SHEETS
| September 30, 2021 | December 31, 2020 | |||||
| (unaudited) | ||||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 58,371,572 | $ | 50,068,728 | ||
| Investments | 945,066 | 1,909,368 | ||||
| Accounts receivable, net | 4,253,647 | 4,574,932 | ||||
| Inventory, net | 4,433,389 | 3,933,987 | ||||
| Prepaid expenses and other current assets | 685,449 | 771,666 | ||||
| Prepaid income taxes | 2,899,939 | 2,477,211 | ||||
| Total current assets | 71,589,062 | 63,735,892 | ||||
| Property and equipment, net | 2,110,377 | 2,120,148 | ||||
| Intangible assets, net | 1,054,641 | 960,885 | ||||
| Operating lease right-of-use asset | 2,548,702 | 2,715,030 | ||||
| Deferred income taxes, net | 870,028 | 1,272,672 | ||||
| Other assets | 225,749 | 261,993 | ||||
| Total assets | $ | 78,398,559 | $ | 71,066,620 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 842,660 | $ | 657,054 | ||
| Accrued payroll and benefits | 2,413,986 | 1,714,782 | ||||
| Other accrued taxes | 91,254 | 103,981 | ||||
| Warranty reserve | 111,007 | 90,054 | ||||
| Deferred revenue | 2,442,430 | 1,949,259 | ||||
| Current portion of operating lease liability | 272,498 | 255,698 | ||||
| Other current liabilities | 146,435 | 146,435 | ||||
| Total current liabilities | 6,320,270 | 4,917,263 | ||||
| Deferred revenue | 1,910,668 | 2,305,413 | ||||
| Operating lease liability | 2,276,204 | 2,459,332 | ||||
| Total liabilities | 10,507,142 | 9,682,008 | ||||
| Stockholders’ equity: | ||||||
| Common stock | 1,234 | 1,231 | ||||
| Additional paid-in capital | 24,766,697 | 23,676,843 | ||||
| Retained earnings | 43,102,255 | 37,669,451 | ||||
| Accumulated other comprehensive income | 21,231 | 37,087 | ||||
| Total stockholders’ equity | 67,891,417 | 61,384,612 | ||||
| Total liabilities and stockholders’ equity | $ | 78,398,559 | $ | 71,066,620 | ||
IRADIMED CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||
| Revenue | $ | 10,907,302 | $ | 7,699,096 | $ | 29,941,721 | $ | 23,171,329 | ||||
| Cost of revenue | 2,501,745 | 1,958,036 | 7,141,547 | 6,036,353 | ||||||||
| Gross profit | 8,405,557 | 5,741,060 | 22,800,174 | 17,134,976 | ||||||||
| Operating expenses: | ||||||||||||
| General and administrative | 2,252,274 | 2,196,935 | 7,247,262 | 10,062,089 | ||||||||
| Sales and marketing | 2,585,702 | 2,282,491 | 7,434,603 | 7,090,192 | ||||||||
| Research and development | 480,696 | 476,876 | 1,410,192 | 1,389,812 | ||||||||
| Total operating expenses | 5,318,672 | 4,956,302 | 16,092,057 | 18,542,093 | ||||||||
| Income (loss) from operations | 3,086,885 | 784,758 | 6,708,117 | (1,407,117 | ) | |||||||
| Other income, net | 7,143 | 9,352 | 14,675 | 125,706 | ||||||||
| Income (loss) before provision for income taxes | 3,094,028 | 794,110 | 6,722,792 | (1,281,411 | ) | |||||||
| Provision for income tax expense (benefit) | 517,767 | (280,536 | ) | 1,289,988 | (2,012,998 | ) | ||||||
| Net income | $ | 2,576,261 | $ | 1,074,646 | $ | 5,432,804 | $ | 731,587 | ||||
| Net income per share: | ||||||||||||
| Basic | $ | 0.21 | $ | 0.09 | $ | 0.44 | $ | 0.06 | ||||
| Diluted | $ | 0.20 | $ | 0.09 | $ | 0.43 | $ | 0.06 | ||||
| Weighted average shares outstanding: | ||||||||||||
| Basic | 12,331,062 | 12,243,362 | 12,318,476 | 12,071,027 | ||||||||
| Diluted | 12,603,566 | 12,493,309 | 12,570,925 | 12,414,932 | ||||||||
IRADIMED CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
| Nine Months Ended September 30, | ||||||
| 2021 | 2020 | |||||
| Operating activities: | ||||||
| Net income | $ | 5,432,804 | $ | 731,587 | ||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
| Change in allowance for doubtful accounts | (567 | ) | 41,786 | |||
| Change in provision for excess and obsolete inventory | 51,731 | 29,209 | ||||
| Depreciation and amortization | 1,020,223 | 999,812 | ||||
| Loss on disposal of property and equipment | 1,066 | — | ||||
| Stock-based compensation | 1,067,589 | 3,644,115 | ||||
| Deferred income taxes, net | 414,095 | 310,329 | ||||
| Gain on maturities of investments | (13,005 | ) | (8,861 | ) | ||
| Changes in operating assets and liabilities: | ||||||
| Accounts receivable | 321,852 | 2,999,188 | ||||
| Inventory | (344,721 | ) | (1,062,455 | ) | ||
| Prepaid expenses and other current assets | (663,408 | ) | (642,982 | ) | ||
| Other assets | 23,447 | (40,899 | ) | |||
| Accounts payable | (17,076 | ) | (468,615 | ) | ||
| Accrued payroll and benefits | 699,204 | (523,437 | ) | |||
| Other accrued taxes | (12,727 | ) | (473,380 | ) | ||
| Warranty reserve | 20,953 | 5,298 | ||||
| Deferred revenue | 313,381 | 119,658 | ||||
| Prepaid income taxes | (422,728 | ) | (2,335,105 | ) | ||
| Other | — | (3,820 | ) | |||
| Net cash provided by operating activities | 7,892,113 | 3,321,428 | ||||
| Investing activities: | ||||||
| Proceeds from maturities of investments | 950,000 | 480,000 | ||||
| Purchases of property and equipment | (391,303 | ) | (349,283 | ) | ||
| Capitalized intangible assets | (170,234 | ) | (184,281 | ) | ||
| Net cash provided by (used in) investing activities | 388,463 | (53,564 | ) | |||
| Financing activities: | ||||||
| Proceeds from exercises of stock options | 85,615 | 1,722,721 | ||||
| Taxes paid related to net share settlement of equity awards | (63,347 | ) | (922,747 | ) | ||
| Net cash provided by financing activities | 22,268 | 799,974 | ||||
| Net increase in cash and cash equivalents | 8,302,844 | 4,067,838 | ||||
| Cash and cash equivalents, beginning of period | 50,068,728 | 43,481,781 | ||||
| Cash and cash equivalents, end of period | $ | 58,371,572 | $ | 47,549,619 | ||
IRADIMED CORPORATION
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)
Non-GAAP Net Income and Diluted EPS
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||
| Net income | $ | 2,576,261 | $ | 1,074,646 | $ | 5,432,804 | $ | 731,587 | |||||
| Excluding: | |||||||||||||
| Stock-based compensation expense, net of tax expense | 273,175 | 315,507 | 805,998 | 1,070,897 | |||||||||
| Separation expenses, net of tax1 | — | — | — | 2,353,964 | |||||||||
| Non-GAAP net income | $ | 2,849,436 | $ | 1,390,153 | $ | 6,238,802 | $ | 4,156,448 | |||||
| Weighted-average shares outstanding – diluted | 12,603,566 | 12,493,309 | 12,570,925 | 12,414,932 | |||||||||
| Non-GAAP net income per share – diluted | $ | 0.23 | $ | 0.11 | $ | 0.50 | $ | 0.33 | |||||
1 Separation expenses recognized pursuant to a separation agreement as described in Exhibit 10.1 to Form 8-K filed with the Securities and Exchange Commission on June 16, 2020.
Free Cash Flow
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||
| Net cash provided by operating activities | $ | 3,378,341 | $ | 1,334,197 | $ | 7,892,113 | $ | 3,321,428 | ||||
| Less: | ||||||||||||
| Purchases of property and equipment | 150,760 | 48,725 | 391,303 | 349,283 | ||||||||
| Free cash flow | $ | 3,227,581 | $ | 1,285,472 | $ | 7,500,810 | $ | 2,972,145 | ||||
Media Contact:
Chris Scott
Chief Financial and Operating Officer
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
What were IRADIMED's Q3 2021 earnings results?
How does IRADIMED's performance in 2021 compare to 2020?
What is IRADIMED's full-year revenue guidance for 2021?
What factors contributed to IRADIMED's increased net income in Q3 2021?
